Compare TTC & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTC | QGEN |
|---|---|---|
| Founded | 1914 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Tools/Hardware | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.2B |
| IPO Year | 1994 | 1998 |
| Metric | TTC | QGEN |
|---|---|---|
| Price | $92.72 | $40.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $104.00 | $51.30 |
| AVG Volume (30 Days) | 908.3K | ★ 1.8M |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | 1.67% | ★ 5.97% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $2,618,650,000.00 | N/A |
| Revenue This Year | $6.11 | $8.18 |
| Revenue Next Year | $4.45 | $5.66 |
| P/E Ratio | $135.43 | ★ $24.01 |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $62.34 | $38.13 |
| 52 Week High | $105.19 | $57.82 |
| Indicator | TTC | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 38.09 |
| Support Level | $91.80 | N/A |
| Resistance Level | $96.79 | $48.60 |
| Average True Range (ATR) | 2.45 | 0.85 |
| MACD | -0.30 | 0.29 |
| Stochastic Oscillator | 33.20 | 62.75 |
The Toro Co designs, manufactures, markets, and sells professional turf maintenance equipment and services; turf and agricultural irrigation systems; landscaping equipment and lighting products; snow and ice management equipment; construction equipment; and residential yard and snow thrower products. The company operates through Professional and Residential segments, with the Professional segment serving commercial, agricultural, and construction customers and generating the majority of revenue, while the Residential segment focuses on homeowners. Its products are sold through distributors, dealers, retailers, rental centers, and direct channels, with the United States as its primary revenue-generating market.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).